In May 2024, Radformation, Inc., a leading provider of automation solutions for cancer care, announced its acquisition of Limbus AI, a prominent global company specializing in automated contouring software for radiation therapy. This strategic move underscores Radformation’s commitment to innovation and strengthens its AI-driven capabilities in cancer treatment.
With the integration of Limbus’ cutting-edge technology and expertise into their portfolio, Radformation is well-positioned to lead the way in developing innovative software solutions for radiation therapy. The merger between Radformation and Limbus AI aims to combine the strengths of both companies’ platforms, offering an AI-driven contouring solution that represents the pinnacle of technological advancements in the field.
As CEO of Radformation, Kurt Sysock expressed the company’s dedication to enhancing the radiation therapy process by prioritizing efficiency, quality, and patient safety. By leveraging each company’s strengths, this alliance is set to accelerate innovation, expand market reach, and ultimately improve patient outcomes on a global scale.
Karl Otto, CEO of Limbus AI, shared the vision of both companies to introduce groundbreaking software solutions that enhance patient care. By uniting their talented teams, Radformation and Limbus AI are poised to achieve significant milestones together, delivering exceptional results in healthcare technology.
Radformation’s acquisition positions it as a leader in clinical treatment planning with its extensive global presence and diverse product offerings. With its new partnership with Limbus AI